Embryonic ventral mesencephalic grafts to the substantia nigra of MPTP‐treated monkeys: Feasibility relevant to multiple‐target grafting as a therapy for Parkinson's disease

No abstract is available for this paper.

• Publication year

  2002

• Venue

  The Journal of comparative neurology

• Publication date

  2002-01-21

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/cne.10108PMID 11793337
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Statistical Principles in Experimental Design

  2003influential reference
• Simultaneous intrastriatal and intranigral dopaminergic grafts in the parkinsonian rat model: Role of the intranigral graft

  2000influential reference
• Intranigral transplants of GABA-rich striatal tissue induce behavioral recovery in the rat Parkinson model and promote the effects obtained by intrastriatal dopaminergic transplants.

  1999cited by this paper
• Therapeutic Potential of Nerve Growth Factors in Parkinson’s Disease

  1999cited by this paper
• Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient

  1999cited by this paper
• Striatal dopaminergic correlates of stable parkinsonism and degree of recovery in old-world primates one year after MPTP treatment.

  1999cited by this paper
• Intrastriatal Mesencephalic Grafts Affect Neuronal Activity in Basal Ganglia Nuclei and Their Target Structures in a Rat Model of Parkinson’s Disease

  1998cited by this paper
• An immortalized, type-1 astrocyte of mescencephalic origin source of a dopaminergic neurotrophic factor

  1998cited by this paper
• Intranigral transplants of fetal ventral mesencephalic tissue attenuate D1-agonist-induced rotational behavior.

  1997cited by this paper
• Effects of graft-derived dopaminergic innervation on the target neurons of patch and matrix compartments of the striatum.

  1997cited by this paper
• Neurturin and Glial Cell Line-Derived Neurotrophic Factor Receptor-β (GDNFR-β), Novel Proteins Related to GDNF and GDNFR-α with Specific Cellular Patterns of Expression Suggesting Roles in the Developing and Adult Nervous System and in Peripheral Organs

  1997cited by this paper
• ret receptor tyrosine kinase immunoreactivity is altered in glial cell line-derived neurotrophic factor-responsive neurons following lesions of the nigrostriatal and septohippocampal pathways.

  1997cited by this paper
• Immunocytochemical localization of TrkB in the central nervous system of the adult rat

  1997cited by this paper
• Severe long-term 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the vervet monkey (Cercopithecus aethiops sabaeus).

  1997cited by this paper
• Complementary and Overlapping Expression of Glial Cell Line-Derived Neurotrophic Factor (GDNF), c-ret Proto-Oncogene, and GDNF Receptor-α Indicates Multiple Mechanisms of Trophic Actions in the Adult Rat CNS

  1997cited by this paper
• Reconstruction of the striato-nigro-striatal circuitry by simultaneous double dopaminergic grafts: a tracer study using fluorogold and horseradish peroxidase.

  1997cited by this paper
• Fetal nigral transplantation as a therapy for Parkinson's disease.

  1996cited by this paper
• Characterization of a multicomponent receptor for GDNF

  1996influential reference
• Functional receptor for GDNF encoded by the c-ret proto-oncogene

  1996cited by this paper
• Reconstruction of the Nigrostriatal Pathway by Simultaneous Intrastriatal and Intranigral Dopaminergic Transplants

  1996cited by this paper
• Functional fetal nigral grafts in a patient with Parkinson's disease: Chemoanatomic, ultrastructural, and metabolic studies

  1996cited by this paper
• Sham surgery does not ameliorate MPTP-induced behavioral deficits in monkeys.

  1995cited by this paper
• Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test

  1995cited by this paper
• Ontogeny and distribution of glial cell line-derived neurotrophic factor (GDNF) mRNA in rat.

  1995cited by this paper
• GDNF mRNA expression in normal postnatal development, aging, and in Weaver mutant mice.

  1995cited by this paper
• Behavioral Effects of MPTP Administration in the Vervet Monkey

  1994cited by this paper
• Polysynaptic regulation of glutamate receptors and mitochondrial enzyme activities in the basal ganglia of rats with unilateral dopamine depletion

  1994cited by this paper
• Intranigral fetal dopamine grafts induce behavioral compensation in the rat Parkinson model

  1994cited by this paper
• Mesencephalic type 1 astrocytes rescue dopaminergic neurons from death induced by serum deprivation

  1994cited by this paper
• Efficacy of Brain‐Derived Neurotrophic Factor and Neurotrophin‐3 on Neurochemical and Behavioral Deficits Associated with Partial Nigrostriatal Dopamine Lesions

  1994cited by this paper
• Expression of GDNF mRNA in rat and human nervous tissue.

  1994cited by this paper
• Astrocyte-dependent and -independent phases of the development and survival of rat embryonic day 14 mesencephalic, dopaminergic neurons in culture.

  1994cited by this paper
• Dopaminergic neurons in rat ventral midbrain express brain‐derived neurotrophic factor and neurotrophin‐3 mRNAs

  1994cited by this paper
• Temporal and spatial increase of astroglial basic fibroblast growth factor synthesis after 6-hydroxydopamine-induced degeneration of the nigrostriatal dopamine neurons.

  1994cited by this paper
• Regional and cell-specific expression of GDNF in rat brain.

  1993influential reference
• Transplantation of fetal nigral cells reverses the increase of preproenkephalin mRNA levels in the rat striatum caused by 6-OHDA lesion of the dopaminergic nigrostriatal pathway: a quantitative in situ hybridization study.

  1993cited by this paper
• Expression of neurotrophins by midbrain dopaminergic neurons.

  1993cited by this paper
• Neuropeptide messenger RNA expression in the 6-hydroxydopamine-lesioned rat striatum reinnervated by fetal dopaminergic transplants: differential effects of the grafts on preproenkephalin, preprotachykinin and prodynorphin messenger RNA levels.

  1993cited by this paper
• Dopamine receptor interactions: some implications for the treatment of Parkinson's disease.

  1992cited by this paper
• High molecular weight basic fibroblast growth factor-like protein is localized to a subpopulation of mesencephalic dopaminergic neurons in the rat brain.

  1992cited by this paper
• Protection from 1-methyl-4-phenylpyridinium (MPP+) toxicity and stimulation of regrowth of MPP(+)-damaged dopaminergic fibers by treatment of mesencephalic cultures with EGF and basic FGF.

  1992cited by this paper
• Brain-derived neurotrophic factor and neurotrophin-3 mRNAs are expressed in ventral midbrain regions containing dopaminergic neurons.

  1992cited by this paper
• Molecular cloning of rat trkC and distribution of cells expressing messenger RNAs for members of the trk family in the rat central nervous system.

  1992cited by this paper
• The neurotrophic effects of fibroblast growth factors on dopaminergic neurons in vitro are mediated by mesencephalic glia [published erratum appears in J Neurosci 1992 Mar;12(3):685]

  1991cited by this paper
• Regional expression of transforming growth factor-α mRNA in the rat central nervous system

  1991cited by this paper
• Putative chromaffin cell survival and enhanced host‐derived TH‐Fiber innervation following a functional adrenal medulla autograft for Parkinson's disease

  1991cited by this paper
• PDGF B-chain in neurons of the central nervous system, posterior pituitary, and in a transgenic model.

  1991cited by this paper
• Increased proenkephalin mRNA levels in the rat neostriatum following lesion of the ipsilateral nigrostriatal dopamine pathway with 1-methyl-4-phenylpyridinium ion (MPP+): reversal by embryonic nigral dopamine grafts.

  1991cited by this paper
• Regional expression of transforming growth factor-alpha mRNA in the rat central nervous system.

  1991cited by this paper
• Cells that Express Brain‐Derived Neurotrophic Factor mRNA in the Developing Postnatal Rat Brain

  1991cited by this paper
• Expression of acidic and basic fibroblast growth factors in the substantia nigra of rat, monkey, and human.

  1991cited by this paper
• Increase of striatal methionin enkephalin content following lesion of the nigrostriatal dopaminergic pathway in adult rats and reversal following the implantation of embryonic dopaminergic neurons: a quantitative immunohistochemical analysis.

  1991cited by this paper
• Regional distribution of brain‐derived neurotrophic factor mRNA in the adult mouse brain.

  1990influential reference
• Limited recovery of striatal dopaminergic fibers by adrenal medullary grafts in MPTP-treated aging mice.

  1990cited by this paper
• Reversal of experimental parkinsonism by lesions of the subthalamic nucleus.

  1990cited by this paper
• Primate models of movement disorders of basal ganglia origin.

  1990cited by this paper
• Preliminary report on adrenal medullary grafting and cografting with sural nerve in the treatment of hemiparkinson monkeys.

  1990cited by this paper
• Long-term evaluation of hemiparkinsonian monkeys after adrenal autografting or cavitation alone.

  1990cited by this paper
• Intracerebral adrenal medulla grafts: a review.

  1990cited by this paper
• Symptomatic and asymptomatic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates: biochemical changes in striatal regions.

  1989cited by this paper
• The functional anatomy of basal ganglia disorders.

  1989cited by this paper
• Transient behavioral recovery in hemiparkinsonian primates after adrenal medullary allografts.

  1988cited by this paper
• Paraneuronal grafts in unilateral 6-hydroxydopamine-lesioned rats: morphological aspects of adrenal chromaffin and carotid body glomus cell implants.

  1988cited by this paper
• Comparison of adrenal medullary, carotid body and PC12 cell grafts in 6-OHDA lesioned rats.

  1988cited by this paper
• Adrenal medullary autografts into the basal ganglia of Cebus monkeys: graft viability and fine structure.

  1988cited by this paper
• Adrenal medullary autografts into the basal ganglia of Cebus monkeys: injury-induced regeneration.

  1988cited by this paper
• Adrenal medulla grafts enhance recovery of striatal dopaminergic fibers.

  1987cited by this paper
• Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on catecholamines and metabolites in primate brain and CSF.

  1987cited by this paper
• Dendritic release of dopamine in the substantia nigra

  1981cited by this paper
• Altered succinate dehydrogenase activity of basal ganglia following to mesotelencephalic dopaminergic projection.

  1981cited by this paper
• Release of dopamine from dendrites in rat substantia nigra

  1976cited by this paper
• Estimation of nuclear population from microtome sections

  1946cited by this paper

• Brain Repair by Cell Replacement via In Situ Neuronal Reprogramming.

  2021cites this paper
• Emerging regenerative medicine and tissue engineering strategies for Parkinson’s disease

  2020cites this paper
• Tyrosine Hydroxylase Inhibition in Substantia Nigra Decreases Movement Frequency

  2018cites this paper
• Transplantation in the nonhuman primate MPTP model of Parkinson's disease: update and perspectives

  2017influential citation
• Historical perspective of cell transplantation in Parkinson’s disease

  2017cites this paper
• The role of nonhuman primate models in the development of cell-based therapies for Parkinson’s disease

  2017cites this paper
• Transplantation of Embryonic Ventral Mesencephalic Tissue in 6-OHDA Induced Parkinsonism Rat Brain for Cell Based Therapy: A Perspective of Methods

  2016cites this paper
• Neuroprotection by 6-(methylsulfinyl)hexyl isothiocyanate in a 6-hydroxydopamine mouse model of Parkinson׳s disease.

  2014cites this paper
• Rebuilding the nigrostriatal dopamine pathway: 30 years and counting.

  2014cites this paper
• Allopregnanolone and neurogenesis in the nigrostriatal tract

  2014cites this paper
• Characterisation of embryonic ventral mesencephalon grafts in a rat model of Parkinson’s disease

  2013cites this paper
• Exercise Does Not Protect against MPTP-Induced Neurotoxicity in BDNF Happloinsufficent Mice

  2012cites this paper
• Behavioral Assessment in the African Green Monkey After MPTP Administration

  2011cites this paper
• Cell transplantation and gene therapy in Parkinson's disease.

  2011cites this paper
• Rewiring the brain with cell transplantation in Parkinson's disease.

  2011cites this paper
• Extrastriatal Dopaminergic Circuits of the Basal Ganglia

  2010cites this paper
• Gene therapy in hemiparkinsonian rhesus monkeys: long-term survival and behavioral recovery by transplantation of autologous human tyrosine hydroxylase-expressing neural stem cells.

  2010cites this paper
• Embryonic substantia nigra grafts in the mesencephalon send neurites to the host striatum in non‐human primate after overexpression of GDNF

  2009cites this paper
• Cell-Based Therapies for Parkinson's Disease: Past, Present, and Future

  2009cites this paper
• Tissue Transplantation for Parkinson’s Disease

  2009cites this paper
• Genetic Basis of Inherited Macular Dystrophies and Implications for Stem Cell Therapy

  2009cites this paper
• Therapeutic potentials of human embryonic stem cells in Parkinson’s disease

  2008cites this paper
• Embryonic Substantia Nigra Grafts Show Directional Outgrowth to Cografted Striatal Grafts and Potential for Pathway Reconstruction in Nonhuman Primate

  2008cites this paper
• TARGETING AXON GROWTH FROM NEURONS TRAN SPLANTEDINTO THE CENTRAL NER VOUS SYSTEM

  2007cites this paper
• The future of cell therapies in the treatment of Parkinson's disease

  2007cites this paper
• Orthotopic transplantation of immortalized mesencephalic progenitors (CSM14.1 cells) into the substantia nigra of hemiparkinsonian rats induces neuronal differentiation and motoric improvement

  2007cites this paper
• How to improve the survival of the fetal ventral mesencephalic cell transplanted in Parkinson’s disease?

  2007cites this paper
• How to improve the survival of the fetal ventral mesencephalic cell transplanted in Parkinson’s disease?

  2007cites this paper
• Partial depletion of dopamine in substantia nigra impairs motor performance without altering striatal dopamine neurotransmission

  2006cites this paper
• Neural Transplantation in the Nonhuman Primate Model of Parkinson’s Disease

  2006cites this paper
• [Cell therapy and other neuroregenerative strategies in Parkinson's disease (I)].

  2005cites this paper
• Dopamine Release in Substantia Nigra: Release Mechanisms and Physiological Function in Motor Control

  2005cites this paper
• Dopaminergic neurons generated from monkey embryonic stem cells function in a Parkinson primate model.

  2005cites this paper
• Proteomic approach to studying parkinson’s disease

  2004cites this paper
• Article Commentary: A Perspective on Transplantation Therapy and Stem Cells for Parkinson's Disease1

  2004cites this paper
• CDKs: taking on a role as mediators of dopaminergic loss in Parkinson's disease.

  2004cites this paper
• In vivo characterization of somatodendritic dopamine release in the substantia nigra of 6‐hydroxydopamine‐lesioned rats

  2004cites this paper
• Potential use of stem cells in neuroreplacement therapies for neurodegenerative diseases.

  2003cites this paper
• [Stem cells: solution to the problem of transplants in Parkinson's disease?].

  2003cites this paper
• Somatodendritic dopamine release in rat substantia nigra influences motor performance on the accelerating rod.

  2003cites this paper
• Inhibition of Calpains Prevents Neuronal and Behavioral Deficits in an MPTP Mouse Model of Parkinson's Disease

  2003cites this paper
• Cellular replacement therapy for Parkinson's disease--where we are today?

  2002cites this paper
• Grafts in parkinsonism.

  2002cites this paper
• A Multiple Target Neural Transplantation Strategy for Parkinson's Disease

  2002cites this paper
• Book Review: Cellular Replacement Therapy for Parkinson’s Disease—Where We Are Today?

  2002cites this paper